Skip to content

#交易/融资

Today 1 items
TodayOct 16Fri
  1. biopharmadive.com49

    Belgian startup revives Galapagos CAR-T research

    Lakefront Biotherapeutics, formerly Galapagos, has sold its cell therapy programmes to Belgian startup Armed Cell Therapeutics for 8 million euros up front, with up to $230 million more in future payments. The deal covers two armed CAR-T therapies nearing human testing in non-Hodkin lymphoma and small cell lung cancer, plus three undisclosed preclinical projects. Armed Cell named Willemijn Kremer, a former Galapagos cell therapy executive, as CEO, replacing interim CEO Paul Stoffels.

    Why it matters: Revives shelved CAR-T programmes under a new company after Galapagos wound down its cell therapy research.

Oct 15Thu
  1. biospace.com69

    AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro

    AstraZeneca will pay insitro up to $1.5 billion to discover drug targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies using insitro's Virtual Human AI platform. Insitro receives $40 million upfront and up to $1.46 billion in milestones plus royalties, while AstraZeneca advances any candidates through development. The deal adds to AstraZeneca's MASH work, which includes the Phase 1 anti-fibrotic asset AZD2389.

    Why it matters: A large pharma-AI target discovery deal in MASH and cardiomyopathies, indications where AstraZeneca has recent setbacks.

  2. biospace.com49

    Stoffels strikes up new biotech in return to Galapagos cell therapy mission

    Former Galapagos CEO Paul Stoffels has founded Armed Cell Therapeutics in Belgium to acquire the CAR T cell therapy programs that Galapagos, now Lakefront Biotherapeutics, abandoned in October 2025. Armed pays about $9 million upfront plus $230 million in milestones and royalties, just under $240 million in total, for the preclinical assets, which originated from AboundBio and target non-Hodgkin lymphoma and small cell lung cancer. Stoffels will chair the board, Willemien Kremer becomes CEO, and the company aims to move the programs into the clinic.

  3. biopharmadive.com61

    Iambic, an AI drug discovery specialist, banks $150M in an IPO

    Iambic Therapeutics, an AI drug discovery startup, raised $150 million in an IPO, selling close to 9.4 million shares at $16 each and trading on the Nasdaq from Thursday under the ticker "IAM." The company has drawn $462 million in private funding since 2019 and will use the proceeds to advance its first drug, IAM1363, an oral tyrosine kinase inhibitor for HER2-positive solid tumors that showed anti-tumor activity and encouraging safety in a Phase 1 study, with a registrational trial possibly beginning in 2027. Behind it are IAM217, targeting KIF18A in ovarian and triple-negative breast cancers, and a CDK2/CDK4-targeting prospect, both potentially entering testing next year.

    Why it matters: The offering adds to a wave of AI drug discovery startups testing whether public investors will back the technology.

  4. biospace.com65

    Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers

    Gilead Sciences has licensed three dual-masked T cell engagers for solid tumors from Vir Biotechnology in a deal worth up to $1.87 billion, including $135 million in upfront and near-term payments. The upfront portion comprises $65 million in cash and a $25 million equity stake, plus $45 million in near-term preclinical milestones, with $1.74 billion in additional milestones possible. Vir will run discovery before handing development of promising assets to Gilead; analysts at H.C. Wainwright await VIR-5818 Phase 1 data in HER2-targeted solid tumors by year-end.

Oct 14Wed
  1. biospace.com63

    Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs

    Zealand Pharma will pay Generate:Biomedicines $30 million upfront, up to $35 million in early preclinical milestones and nearly $1.2 billion in development, regulatory and commercial milestones, plus tiered royalties, to access Generate's generative AI platform for designing protein therapeutics for obesity and metabolic diseases. Generate handles research through candidate selection; Zealand leads clinical development, regulatory and commercialization. The deal follows mixed Zealand readouts for petrelintide and survodutide.

    Why it matters: Large AI drug-discovery alliance in obesity adds Generate's platform to Zealand's metabolic pipeline after mixed trial results.

  2. biopharmadive.com56

    Another Paragon spinout goes public through reverse merger

    Alaunos Therapeutics acquired Velaris Therapeutics, Paragon Labs' ninth spinout, in a reverse merger that takes the cardiopulmonary disease drug developer public. Fairmount Funds, which founded Paragon in 2021, led a concurrent private placement of about $350 million, with investors including Venrock, Wellington Management and T. Rowe Price accounts, funding operations into 2029. Four of the combined company's five board directors will come from or be picked by Fairmount, and the business will advance Velaris' programs plus an obesity and metabolic disorder drug from Alaunos.

    Why it matters: Reverse mergers have surged to more than two dozen announced this year, matching IPO counts, and Velaris extends the Paragon-Fairmount model.

  3. statnews.com71

    STAT+: BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8 billion

    BlackRock is buying Welsh, Carson, Anderson & Stowe's majority stake in Humana's CenterWell Senior Primary Care, a network of 150 Medicare Advantage-focused clinics, in a $2.8 billion transaction announced Tuesday. Welsh Carson, which has invested at least $1.8 billion since 2020, is exiting after more than six years. Humana said the deal will over the next two years fund clinic operations, new clinics and other strategic acquisitions.

    Why it matters: A $2.8 billion ownership change at 150 Medicare Advantage clinics reshapes who funds Humana's primary care growth.

  4. biopharmadive.com64

    Roche extends China deal streak with $1B pact for RNAi obesity drug

    Roche licensed an experimental RNA interference obesity medicine targeting ALK7 from China-based Rona Therapeutics, paying $100 million upfront for full ownership and up to just over $1 billion in milestones plus royalties. The drug joins five other experimental obesity medicines in Roche's pipeline. It is Roche's fifth deal with a China-based drugmaker since the end of August and 10th since the beginning of 2025.

Oct 13Tue
  1. biospace.com65

    Roche expands obesity R&D footprint with Rona deal worth $1B+

    Roche has licensed an RNAi-based ALK7 obesity drug candidate from China's Rona Therapeutics, paying up to $100 million upfront and in near-term milestones plus as much as $1.06 billion in future milestones. ALK7 inhibition may reduce fat deposits while preserving muscle, an option GLP-1 drugs lack. The deal follows Roche returning its anti-myostatin therapy emugrobart to subsidiary Chugai after a mid-stage analysis found it unlikely to produce meaningful weight loss.

  2. biospace.com56

    Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins

    Pfizer has signed a deal with Paris-based Enodia Therapeutics worth up to $500 million, covering an upfront payment plus research, development and sales milestones, with tiered royalties on net sales. Enodia will screen, optimize and develop small-molecule inhibitors of the Sec61 membrane protein complex, while Pfizer handles clinical studies, manufacturing, regulatory and commercial work. Target indications are not yet specified. Pfizer's venture arm had co-led Enodia's €20.7 million ($25 million) seed round in January.

    Why it matters: Pfizer commits over $500 million to a Sec61-targeting platform less than a year after the biotech's launch.

  3. biocentury.com66

    Viatris adds analgesics, pipeline via Pacira takeout: Deals Report

    Viatris will pay nearly $1.7 billion to acquire Pacira, gaining non-opioid analgesics Exparel bupivacaine for acute postsurgical pain and Zilretta sustained-release triamcinolone acetonide for osteoarthritis pain. The two products generated $350.5 million in revenue for Pacira in the first six months of 2026, including $291.1 million from Exparel. The deal comes amid a slow period for biotech M&A.

    Why it matters: Large-cap acquisition adds marketed non-opioid pain products to Viatris' portfolio.

  4. biopharmadive.com47

    Parkinson’s cell therapy developer files to go public

    Aspen Neuroscience, founded in 2018, has filed registration documents to list on the Nasdaq under ticker "ASPE" and would be the first Parkinson's-focused cell therapy developer to go public in the U.S. Its lead therapy sasineprocel, or ANPD001, reprograms a patient's own cells into dopamine-producing neurons and is entering late-stage testing after an early-stage trial. Aspen has raised about $347 million, posted a $62 million net loss in 2025 and nearly $37 million in the first six months of this year, and warned of substantial doubt about its ability to continue as a going concern without substantial additional capital.

Oct 12Mon
  1. biospace.com49

    GSK pledges $800M to add biologics production capabilities in Pennsylvania

    GSK will invest more than $800 million to build an innovation and manufacturing hub in Upper Merion Township, Pennsylvania, adding a biologics production facility, an R&D pilot plant, a centralized quality control lab and a manufacturing science and technology hub. Demolition and construction start next year. Pennsylvania officials expect more than 300 new jobs over five years, with about 4,500 existing jobs retained, and the project is eligible for state tax benefits.

    Why it matters: Large manufacturing investment signals GSK's biologics capacity strategy in the US.

Oct 9Fri
  1. biospace.com54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

  2. biospace.com80

    How Abogen went from COVID hype to a $7.8B Novartis deal

    Novartis has taken an exclusive worldwide license to ABO2203, Abogen Biosciences' mRNA-encoded CD19xCD3 T cell engager for B-cell malignancies and autoimmune diseases, paying $575 million upfront with up to roughly $7.2 billion in potential option, milestone and royalty payments. Early data in relapsed or refractory B-cell non-Hodgkin lymphoma showed overall response rates of 33%, 67% and 100% across dose cohorts, with no CRS or ICANS reported. The deal, which also gives Novartis options on further Abogen RNA platform programs, marks Abogen's shift beyond its faded COVID vaccine business.

    Why it matters: Large upfront payment signals big-pharma validation of in vivo mRNA T cell engagers and Abogen's post-COVID pivot.

  3. biospace.com63

    Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business

    Viatris has agreed to buy Pacira BioSciences for $1.65 billion, or $36.50 per share in cash, to build a non-opioid pain therapy business. The deal adds Exparel, a post-surgical injectable bupivacaine, and Zilretta, an injectable corticosteroid for osteoarthritis knee pain, which generated sales of $587 million and $121 million respectively in the second half of 2025 and first half of this year. Viatris expects to close the takeover by the end of the year, while the FDA is due to rule on its fast-acting meloxicam filing for moderate-to-severe acute pain by Dec. 27.

    Why it matters: Shows how Viatris pairs a $1.65 billion acquisition with a pending FDA decision to build a non-opioid pain franchise.

  4. biopharmadive.com61

    TRex Bio prices $117M IPO to support immune drug work

    TRex Bio priced a $117 million IPO, selling 8,333,334 shares at $14 each, and begins trading Friday on Nasdaq under "TRXB." The company is developing Treg-activating drugs for immunological conditions, including TRB-061, in a Phase 1 trial with topline data expected in 2027, and TRB-071 for inflammatory bowel disease, which could enter testing next year. Eli Lilly, TRex's largest equity holder at about 24% pre-IPO, and Johnson & Johnson have licensed or optioned treatments discovered by TRex, which has raised $220 million in venture financing to date.

    Why it matters: IPO shows continued investor appetite for immune-focused biotechs, with six of 23 drug developers going public in 2026 working on immune diseases.

  5. biocentury.com48

    Matchpoint’s $150M tops the week’s private rounds: Venture Report

    Matchpoint Therapeutics, a Watertown, Mass.-based biotech, raised a $150 million series B to take its lead program to proof of concept, four years after a $100 million series A. It was one of at least four companies closing venture rounds of at least $25 million in the past week, while European VC Forbion raised a record €2.3 billion in new funds.

    Why it matters: Matchpoint's $150 million series B was the largest private biotech round of the week, alongside Forbion's €2.3 billion fundraise.

  6. biopharmadive.com52

    In the hunt for reverse merger targets, Caribou could be prized game

    Caribou Biosciences, the CRISPR company co-founded by Jennifer Doudna, will stop developing its two off-the-shelf cell therapy programs for blood malignancies, citing a financing environment that CEO Rachel Haurwitz called increasingly challenging. The board has cleared management to evaluate a merger, acquisition or other transactions, with Wedbush Securities as exclusive financial advisor. Caribou ended the second quarter with $114 million in cash and securities, and Leerink analyst Daina Graybosch sees a reverse merger or a sale to Tang Capital as likely outcomes.

    Why it matters: A prominent CRISPR biotech with $114 million in cash is winding down and auctioning itself amid a wave of biotech reverse mergers.

  7. biopharmadive.com61

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    Viatris is buying Pacira BioSciences for $1.65 billion, paying $36.50 per share in cash, a 45% premium, to gain the non-opioid pain drugs Exparel and Zilretta for post-surgical and osteoarthritis knee pain. Pacira's two main products booked $692 million in sales in 2025, up about 4% from 2024. The deal is expected to close by the end of 2026, with generics for Exparel likely from early 2030 and Zilretta patents expiring in 2031.

    Why it matters: Large-cap pharma M&A in pain therapeutics, with near-term patent cliffs on the acquired products.

Oct 8Thu
  1. statnews.com40

    STAT+: Roche goes beyond licensing in deal with Chinese biotech

    Roche is partnering with Chinese startup Defand Therapeutics to discover new medicines rather than merely license existing drug candidates, a departure from how pharma companies have approached China in recent years. Defand will discover multiple molecular glue degraders for cancer and immune-driven diseases, drugs designed to attach to problematic proteins and destroy them. Interest in the class grew after Revolution Medicines' molecular glue Rasonque nearly doubled survival in pancreatic cancer patients. Financial terms and next milestones were not disclosed.

  2. biospace.com66

    Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset

    Preclinical Matchpoint Therapeutics has raised a $150 million series B co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures, Atlas Venture, Access Biotechnology and the T1D Fund. The money will advance MPT-062, an oral T cell modulator for autoimmune and inflammatory conditions, into human trials starting next year. Matchpoint also has a July 2025 deal with Novartis, which paid $60 million upfront for its ACE platform and could owe up to $1 billion in milestones plus royalties.

    Why it matters: A large series B funds a first-in-class oral autoimmune program before it reaches human trials, against a market trend favouring later-stage assets.

  3. statnews.com51

    STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines

    Roche has signed a discovery collaboration with Chinese startup Defand Therapeutics to develop molecular glue medicines for cancer and immune-driven diseases. Financial terms were not disclosed, but a source said the deal could be worth close to $1 billion in upfront fees and milestone payments tied to preclinical, clinical and regulatory goals. Defand will discover and develop multiple drugs under the partnership.

    Why it matters: A big pharma pays a Chinese biotech for discovery-stage molecular glue work rather than late-stage assets.

  4. biopharmadive.com65

    Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

    Caribou Biosciences, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, is discontinuing research, laying off staff and seeking strategic alternatives after failing to raise money to advance its allogeneic CAR-T programs. The move ends work on vispa-cel, which was ready for Phase 3 testing in lymphoma with an FDA-agreed trial design, and CB-011, in testing for multiple myeloma. The board will weigh mergers, acquisitions or other transactions, with the workforce reduction mostly done by year-end.

Oct 7Wed
  1. biospace.com69

    Biotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies

    Forbion has raised €2.3 billion ($2.6 billion) across two new funds, Growth Opportunities Fund IV and Ventures Fund VIII, its largest raise ever, to back some 30 high-potential drugmakers, from pre-clinical and early clinical-stage biotechs to private growth, crossover and public investments. Eli Lilly participated alongside KfW Capital, PGM and Kauffman Foundation. The Dutch firm now has approximately €7.5 billion ($8.42 billion) in assets under management across a portfolio of more than 140 companies.

    Why it matters: One of the largest life sciences VC raises in five years signals where biotech capital is flowing.

  2. biospace.com49

    Bayer commits $2.2B to build pharma manufacturing plant in Ohio

    Bayer will invest $2.2 billion in a drug substance and drug product manufacturing facility in New Albany, Ohio, serving U.S. and global markets in oncology, cardiovascular disease and renal care. One drug substance module is expected to become operational in 2031 and a second in 2034. Ohio officials expect about 600 permanent jobs plus about 1,500 construction roles, with JobsOhio investing up to $30 million in a training center opening next summer.

    Why it matters: A $2.2 billion U.S. reshoring investment by Bayer adds capacity in a tight biomanufacturing labor market.

  3. biospace.com67

    Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up

    Caribou Biosciences, co-founded by CRISPR pioneer Jennifer Doudna, will end all R&D activities, halt its clinical trials and make substantial staff cuts after failing to secure financing for its allogeneic CAR-T programs, including vispa-cel for B cell non-Hodgkin lymphoma and CB-011 for multiple myeloma. The company, which had $113.8 million in cash as of June 30 and expects $15 million to $19 million in restructuring costs, will explore a merger, acquisition or other strategic transactions.

    Why it matters: Collapse of a well-funded allogeneic CAR-T developer signals how far financing has frozen in that field.

  4. biospace.com40

    Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

    Genmab and AbbVie's bispecific antibody Epkinly, approved in May 2023 for diffuse large B cell lymphoma after at least two prior systemic lines, cut risk of disease progression or death by 51% in a Phase 3 trial when combined with R-CHOP in the frontline setting. In deals, Shionogi bought IntraBio for $2 billion, Novartis committed up to $7.8 billion to Abogen Biosciences, Eli Lilly added up to $870 million with Gate Bioscience, and Sanofi and Regeneron renewed their collaboration with a $1 billion upfront. Sarepta shared Elevidys data in older Duchenne patients at the World Muscle Society meeting, with Jefferies citing upcoming readouts and an FDA decision on Amondys 45 and Vyondys 53.

  5. biocentury.com41

    RougeTx: Reattaching pericytes to stabilize vessels in HHT

    RougeTx, a Naarden, Netherlands-based spinout of Leiden University Medical Center, launched with a $58 million series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners to advance RTX-001 into the clinic. The oral small molecule, designed for once-daily dosing, aims to stabilize blood vessels by reattaching pericytes rather than suppressing angiogenesis in hereditary hemorrhagic telangiectasia. The company will now move RTX-001 toward clinical testing in HHT.

    Why it matters: Series A funds a first-in-class oral approach to a rare vascular disease with no such option named.

  6. biopharmadive.com60

    Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds

    Forbion, a Netherlands-based venture firm focused on life sciences, raised 2.3 billion euros ($2.6 billion) across two funds, Forbion Growth Opportunities IV and Forbion Ventures Fund VIII, its largest fundraise to date. The funds have capacity to invest in as many as 30 young companies; recent investments include Sling Therapeutics and Solstice Oncology. Backers include MN, PGGM, the Kauffman Foundation, KfW Capital and Eli Lilly, and Forbion now has 7.5 billion euros under management.

    Why it matters: Europe's largest life sciences venture fund raised its biggest sum yet while European biotech faces declining investment and clinical trial activity.

Oct 6Tue
  1. biospace.com67

    Shionogi makes $2B rare disease play with IntraBio buy

    Shionogi will acquire IntraBio for $2 billion upfront, gaining Aqneursa, the first and only approved treatment for ataxia-telangiectasia and the only therapy for Niemann-Pick disease type C, an ultrarare genetic disorder with around 1,000 potential US patients. Aqneursa generated $68 million in net sales last year in NPC, and Jefferies estimates $1 billion in global peak sales. The deal extends a rare disease build-out that includes Radicava, acquired from Tanabe Pharma for $2.5 billion, and IntraBio continues studying Aqneursa in GM2 gangliosidoses and other disorders.

  2. biopharmadive.com66

    GE HealthCare to acquire Sofie Biosciences for $945M

    GE HealthCare has agreed to buy Sofie Biosciences for $945 million in cash to expand its U.S. radiopharmaceutical manufacturing and distribution. Sofie, a contract manufacturing organization with 15 U.S. CMO sites making PET radiopharmaceuticals, will join GE HealthCare's pharmaceutical diagnostics business PDx, with the deal expected to close in the first half of 2027. GE HealthCare also gains U.S. rights to FAPI-74, a pan-cancer PET radiotracer, and expects the acquisition to add to revenue growth and adjusted EPS in the first full year of ownership.

    Why it matters: Acquisition adds U.S. manufacturing capacity for time-sensitive F18 PET radiopharmaceuticals and rights to a pan-cancer radiotracer.

  3. biocentury.com72

    Building again in rare diseases, Shionogi pays $2B for IntraBio

    Shionogi will acquire privately held IntraBio for $2 billion to expand its rare disease portfolio, gaining rights to Aqneursa levacetylleucine (IB1001), a modified N-acetyl-L-leucine amino acid therapy targeting neurological dysfunction and degeneration. The drug is approved for two indications, including one first-in-disease approval. The deal awaits completion.

    Why it matters: $2 billion rare-disease acquisition adds an approved first-in-disease neurological therapy to Shionogi's portfolio.

  4. biopharmadive.com65

    Shionogi pays $2B to acquire a rare disease startup

    Shionogi agreed on Oct. 5, 2026 to acquire Texas-based IntraBio for $2 billion in cash, gaining Aqneursa, a marketed treatment for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio, which will become a wholly owned subsidiary of Shionogi's U.S. division, reported $68 million in sales in 2025. Shionogi said it will review the deal's effect on its outlook for the fiscal year ending next March.

Oct 5Mon
  1. biospace.com60

    Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks

    Eli Lilly has expanded its alliance with Gate Bioscience in a deal worth up to more than $870 million, adding one new target with the option of a second to their existing collaboration on Gate's Molecular Gate discovery engine for difficult-to-drug extracellular proteins. Gate, which signed an initial deal with Lilly worth up to $856 million in July 2025, will receive an undisclosed upfront payment plus payments on preclinical, clinical and commercial milestones and tiered royalties. Gate leads discovery while Lilly takes an exclusive worldwide license and handles development from later-stage preclinical work through commercialization; no indications have been disclosed.

    Why it matters: Lilly is committing another $870 million to Gate's Molecular Gate platform, deepening a fast-repeat collaboration on a new drug class.

  2. biopharmadive.com40

    Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

    The Nobel Prize in Physiology or Medicine went to Peter Hegemann, Georg Nagel and Karl Deisseroth for optogenetics, a light-based method for studying neurons. Alector licensed its preclinical Parkinson's therapy AL050 to Roche's Genentech for $100 million in guaranteed cash and up to $1.17 billion in milestones plus royalties. Separately, the FDA approved Lilly's Jaypirca as a first-line treatment for CLL or SLL patients without a 17p deletion.

    Why it matters: Nobel recognition for optogenetics and a sizeable Roche-Alector brain drug deal matter to neuroscience-focused readers.

  3. biospace.com58

    Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset

    Genentech is paying $100 million upfront for exclusive development and commercialization rights to Alector's preclinical AL050, a blood-brain barrier-crossing glucocerebrosidase enzyme replacement therapy for neurodegenerative diseases including Parkinson's and Alzheimer's, with up to $1.17 billion in milestones plus tiered royalties. Genentech will handle development, regulatory, manufacturing and commercialization, while Alector retains its Alector Brain Carrier platform. The deal extends Alector's cash runway into 2029 and funds its anti-Aβ antibody AL137 and siRNA programs.

  4. biospace.com62

    CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

    CSL will pay Alentis Therapeutics $355 million upfront, with up to $1.2 billion more, to co-develop and co-promote the claudin-1-targeting antibody lixudebart. The drug is in the Phase 2 RENAL trial for AAV-RPGN, a rare autoimmune kidney disease, and is also planned for mid-stage development in FSGS and PSC, with CSL funding these studies and any approved product profits split 55/45 in CSL's favour. An FDA orphan drug designation for IPF, granted in May 2024, sits outside the deal.

Oct 3Sat
  1. biocentury.com67

    Novartis turns to mRNA-encoded engagers for B cell depletion

    Novartis is paying Suzhou Abogen Biosciences $575 million up front for exclusive worldwide rights to ABO2203, an mRNA-encoded CD19 x CD3 T cell engager for autoimmune indications, plus options on undisclosed next-generation assets from Abogen's RNA platform. Abogen could receive up to $7.2 billion in milestones if all options are exercised. Early clinical data support the mRNA-encoded T cell engager approach, which adds a new modality to B cell-depleting therapies for autoimmune diseases.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org